UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.85 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 42.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 135,231 shares of the company's stock after buying an additional 40,436 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.14% of Scholar Rock worth $5,845,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. KBC Group NV bought a new stake in Scholar Rock during the 4th quarter valued at $131,000. Rhumbline Advisers raised its position in shares of Scholar Rock by 13.2% during the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after buying an additional 13,247 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Scholar Rock in the 4th quarter worth approximately $274,000. New York State Common Retirement Fund lifted its stake in shares of Scholar Rock by 117.5% in the 4th quarter. New York State Common Retirement Fund now owns 22,586 shares of the company's stock worth $976,000 after acquiring an additional 12,200 shares during the period. Finally, Global Retirement Partners LLC boosted its holdings in shares of Scholar Rock by 584.7% in the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 766 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Scholar Rock Price Performance

NASDAQ:SRRK traded down $0.12 during trading hours on Wednesday, reaching $30.82. 1,153,170 shares of the company's stock were exchanged, compared to its average volume of 1,267,644. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $2.93 billion, a P/E ratio of -13.11 and a beta of 0.37. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The business's 50-day simple moving average is $30.29 and its two-hundred day simple moving average is $36.08.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter in the prior year, the business posted ($0.59) earnings per share. Sell-side analysts expect that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Insider Activity at Scholar Rock

In related news, Director Jeffrey S. Flier sold 6,075 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.73, for a total value of $180,609.75. Following the completion of the sale, the director now owns 24,070 shares in the company, valued at approximately $715,601.10. This represents a 20.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the sale, the chief financial officer now directly owns 111,345 shares in the company, valued at approximately $3,966,108.90. This trade represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 181,798 shares of company stock worth $6,284,738 in the last quarter. 13.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Wedbush reissued an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a report on Wednesday, May 14th. Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.